Synopsis
Synopsis
0
KDMF
0
VMF
0
Europe
0
Australia
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Benazapril
2. Benazepril
3. Benzazepril
4. Briem
5. Cgs-14824-a
6. Cgs-14824a
7. Cibacne
8. Cibacen
9. Labopal
10. Lotensin
1. 86541-74-4
2. Benazepril Hcl
3. Lotensin
4. Cibacen
5. Cibacene
6. Briem
7. Tensanil
8. Zinadril
9. Cibace
10. Labopol
11. Cgs 14824a Hcl
12. Benazepril (hydrochloride)
13. Cgs 14824a
14. Nsc-758920
15. Cgs-14824a Hcl
16. Chebi:3012
17. N1sn99t69t
18. (3s)-3-(((1s)-1-carboxy-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-1h-1-benzazepine-1-acetic Acid, 3-ethyl Ester, Monohydrochloride
19. (3s)-3-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1h-1-benzazepine-1-acetic Acid Hydrochloride
20. 86541-74-4 (hcl)
21. Cibacen Chf
22. Dsstox_cid_25922
23. Dsstox_rid_81225
24. Dsstox_gsid_45922
25. 1h-1-benzazepine-1-acetic Acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, Monohydrochloride, (s-(r*,r*))-
26. 2-((s)-3-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1h-benzo[b]azepin-1-yl)acetic Acid Hydrochloride
27. 2-[(3s)-3-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic Acid;hydrochloride
28. 2-[(3s)-3-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]acetic Acid Hydrochloride
29. Smr000469199
30. Cas-86541-74-4
31. Mfcd00895734
32. Unii-n1sn99t69t
33. Ncgc00095132-01
34. Lotensin (tn)
35. 2-((s)-3-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)-2-oxo-2,3,4,5-tetrahydro-1h-benzo[b]azepin-1-yl)acetic Acid Hydrochloride
36. Benazeprilhydrochloride
37. Benazepril Hydrochloride [usan:usp:jan]
38. Benazepril Monohydrochloride
39. Chembl1694
40. Schembl42194
41. Benazepril Hydrochloride,(s)
42. Mls001076668
43. Mls001333171
44. Mls001333172
45. Mls001401429
46. Spectrum1505200
47. Benazepril Hydrochloride- Bio-x
48. Dtxsid9045922
49. Benazepril For System Suitability
50. Hy-b0093a
51. Bcpp000350
52. Hms1922l07
53. Pharmakon1600-01505200
54. Twt-8154
55. Benazepril Hydrochloride (jan/usp)
56. Tox21_111441
57. Benazepril Hydrochloride [mi]
58. Ccg-39520
59. Nsc758920
60. S1284
61. Benazepril Hydrochloride [jan]
62. Akos015888536
63. Tox21_111441_1
64. Bcp9000387
65. Benazepril Hydrochloride [hsdb]
66. Benazepril Hydrochloride [usan]
67. Cs-1796
68. Ks-1397
69. Nc00211
70. Nsc 758920
71. Benazepril Hydrochloride [mart.]
72. Benazepril Hydrochloride [usp-rs]
73. Benazepril Hydrochloride [who-dd]
74. Ncgc00165740-05
75. (3s)-3-[(1s)-1-ethoxycarbonyl-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo-1h-1-benzazepine-1-acetic Acid Hydrochloride
76. 1h-1-benzazepine-1-acetic Acid, 2,3,4,5-tetrahydro-3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2-oxo-, Monohydrochloride, (s-(r*,r*))-
77. Bb164237
78. B3611
79. Sw197591-3
80. Benazepril Hydrochloride [ep Impurity]
81. Benazepril Hydrochloride [orange Book]
82. Benazepril Hydrochloride [usp Impurity]
83. Benazepril Hydrochloride [usp Monograph]
84. C07701
85. D00620
86. Lotrel Component Benazepril Hydrochloride
87. Benazepril Hydrochloride, >=98% (hplc), Solid
88. A841712
89. Benazepril Hydrochloride Component Cardalis
90. Benazepril Hydrochloride Component Of Lotrel
91. Cardalis Component Benazepril Hydrochloride
92. Sr-01000762893
93. Sr-01000762893-3
94. Benazepril Hydrochloride [ema Epar Veterinary]
95. Fortekor Plus Component Benazepril Hydrochloride
96. Lotensin Hct Component Benazepril Hydrochloride
97. Q27105927
98. Benazepril Hydrochloride Component Of Lotensin Hct
99. Benazepril Hydrochloride Component Of Fortekor Plus
100. Benazepril Hydrochloride, Vetranal(tm), Analytical Standard
101. Benazepril Hydrochloride, European Pharmacopoeia (ep) Reference Standard
102. Benazepril For System Suitability, European Pharmacopoeia (ep) Reference Standard
103. Benazepril Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
104. Benazepril Hydrochloride, United States Pharmacopeia (usp) Reference Standard
105. [(3s)-3-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1h-1-benzazepin-1-yl]acetic Acid Hydrochloride
106. 2-[(3s)-3-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic Acid Hydrochloride;benazepril Hydrochloride
Molecular Weight | 460.9 g/mol |
---|---|
Molecular Formula | C24H29ClN2O5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 10 |
Exact Mass | 460.1764997 g/mol |
Monoisotopic Mass | 460.1764997 g/mol |
Topological Polar Surface Area | 95.9 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 619 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Benazepril hydrochloride |
PubMed Health | Benazepril (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Renal Protective Agent |
Drug Label | Benazepril hydrochloride is a white to off-white crystalline powder, soluble (> 100 mg/mL) in water, in ethanol, and in methanol. BenazeprilC24H28N2O5HCl M.W. 460.96Benazeprilat, the active metabolite of benazepril, is a non-sulfhydryl angiotensin-co.. |
Active Ingredient | Benazepril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Ranbaxy; Ivax Sub Teva Pharms; Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Zydus Pharms Usa; Biokey; Sandoz; Prinston; Mylan |
2 of 4 | |
---|---|
Drug Name | Lotensin |
Drug Label | Benazepril hydrochloride is a white to off-white crystalline powder, soluble (>100 mg/mL) in water, in ethanol, and in methanol. Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-be.. |
Active Ingredient | Benazepril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Us Pharms Holdings I |
3 of 4 | |
---|---|
Drug Name | Benazepril hydrochloride |
PubMed Health | Benazepril (By mouth) |
Drug Classes | Antihypertensive, Cardiovascular Agent, Renal Protective Agent |
Drug Label | Benazepril hydrochloride is a white to off-white crystalline powder, soluble (> 100 mg/mL) in water, in ethanol, and in methanol. BenazeprilC24H28N2O5HCl M.W. 460.96Benazeprilat, the active metabolite of benazepril, is a non-sulfhydryl angiotensin-co.. |
Active Ingredient | Benazepril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Ranbaxy; Ivax Sub Teva Pharms; Actavis Labs Fl; Teva; Apotex; Aurobindo Pharma; Zydus Pharms Usa; Biokey; Sandoz; Prinston; Mylan |
4 of 4 | |
---|---|
Drug Name | Lotensin |
Drug Label | Benazepril hydrochloride is a white to off-white crystalline powder, soluble (>100 mg/mL) in water, in ethanol, and in methanol. Its chemical name is benazepril 3-[[1-(ethoxy-carbonyl)-3-phenyl-(1S)-propyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-be.. |
Active Ingredient | Benazepril hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Us Pharms Holdings I |
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Benazepril Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Benazepril Hydrochloride manufacturer or Benazepril Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Benazepril Hydrochloride manufacturer or Benazepril Hydrochloride supplier.
PharmaCompass also assists you with knowing the Benazepril Hydrochloride API Price utilized in the formulation of products. Benazepril Hydrochloride API Price is not always fixed or binding as the Benazepril Hydrochloride Price is obtained through a variety of data sources. The Benazepril Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A KB-65121 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of KB-65121, including repackagers and relabelers. The FDA regulates KB-65121 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. KB-65121 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of KB-65121 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A KB-65121 supplier is an individual or a company that provides KB-65121 active pharmaceutical ingredient (API) or KB-65121 finished formulations upon request. The KB-65121 suppliers may include KB-65121 API manufacturers, exporters, distributors and traders.
click here to find a list of KB-65121 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A KB-65121 DMF (Drug Master File) is a document detailing the whole manufacturing process of KB-65121 active pharmaceutical ingredient (API) in detail. Different forms of KB-65121 DMFs exist exist since differing nations have different regulations, such as KB-65121 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A KB-65121 DMF submitted to regulatory agencies in the US is known as a USDMF. KB-65121 USDMF includes data on KB-65121's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The KB-65121 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of KB-65121 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The KB-65121 Drug Master File in Japan (KB-65121 JDMF) empowers KB-65121 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the KB-65121 JDMF during the approval evaluation for pharmaceutical products. At the time of KB-65121 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of KB-65121 suppliers with JDMF on PharmaCompass.
A KB-65121 CEP of the European Pharmacopoeia monograph is often referred to as a KB-65121 Certificate of Suitability (COS). The purpose of a KB-65121 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of KB-65121 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of KB-65121 to their clients by showing that a KB-65121 CEP has been issued for it. The manufacturer submits a KB-65121 CEP (COS) as part of the market authorization procedure, and it takes on the role of a KB-65121 CEP holder for the record. Additionally, the data presented in the KB-65121 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the KB-65121 DMF.
A KB-65121 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. KB-65121 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of KB-65121 suppliers with CEP (COS) on PharmaCompass.
A KB-65121 written confirmation (KB-65121 WC) is an official document issued by a regulatory agency to a KB-65121 manufacturer, verifying that the manufacturing facility of a KB-65121 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting KB-65121 APIs or KB-65121 finished pharmaceutical products to another nation, regulatory agencies frequently require a KB-65121 WC (written confirmation) as part of the regulatory process.
click here to find a list of KB-65121 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing KB-65121 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for KB-65121 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture KB-65121 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain KB-65121 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a KB-65121 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of KB-65121 suppliers with NDC on PharmaCompass.
KB-65121 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of KB-65121 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right KB-65121 GMP manufacturer or KB-65121 GMP API supplier for your needs.
A KB-65121 CoA (Certificate of Analysis) is a formal document that attests to KB-65121's compliance with KB-65121 specifications and serves as a tool for batch-level quality control.
KB-65121 CoA mostly includes findings from lab analyses of a specific batch. For each KB-65121 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
KB-65121 may be tested according to a variety of international standards, such as European Pharmacopoeia (KB-65121 EP), KB-65121 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (KB-65121 USP).